Antinociceptive activity of derivatives of improgran and burimamide

Citation
Lb. Hough et al., Antinociceptive activity of derivatives of improgran and burimamide, PHARM BIO B, 65(1), 2000, pp. 61-66
Citations number
18
Categorie Soggetti
Neurosciences & Behavoir
Journal title
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
ISSN journal
00913057 → ACNP
Volume
65
Issue
1
Year of publication
2000
Pages
61 - 66
Database
ISI
SICI code
0091-3057(200001)65:1<61:AAODOI>2.0.ZU;2-Y
Abstract
Improgan, a compound related to H-2 and H-3 antagonists, induces antinocice ption in rodents after intraventricular administration. Characteristics of improgan and its congeners include: (a) morphine-like antinociception on th ermal and mechanical tests in two species; (b) no impairment of motor coord ination or locomotor activity; (c) evidence for a novel, nonopioid mechanis m that is independent of known histamine receptors; (d) lack of tolerance w ith dairy dosing; and (e) unique structure-activity relationships (SARs). P resently, the antinociceptive activity of several new derivatives of improg an was investigated in rats. Among compounds similar to burimamide, VUF4577 (possessing a two-carbon side chain) and VUF4582 (an N-phenyl derivative o f VUF4577) induced complete, dose- and time-dependent antinociception on th e hot-plate and tail-flick tests with no behavioral side effects. These com pounds (with ED50 values of 71-117 nmol) were approximately twice as potent as burimamide itself (a four-carbon derivative). Two other derivatives in which the thiourea group (C=S, known to cause human toxicity) was replaced by either nitroethene (C=CH-NO2, VUF5405) or urea (C=O, VUF5407) also showe d effective, potent antinociception on both assays. The latter compound is the most potent improgan-like drug discovered to date (ED50 = 71 nmol). Fur thermore, positional isomers of antinociceptive compounds either lacked act ivity (VUF5394) or induced toxicity (VUF5393), revealing a high degree of p harmacological specificity. Although the mechanism of improgan antinocicept ion re mains unknown, the present results show promise for the further deve lopment of safe, effective, and potent pain-relieving compounds. (C) 1999 E lsevier Science Inc.